Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 10/20 | 0.73 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15078823 | 1.00 | TBXA2R (0.73) | TBXA2RTBXAS1HDAC8PSEN1PSEN2 | |
| SCHEMBL15053155 | 0.90 | TBXA2R (0.59) | TBXA2RPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL15131733 | 0.87 | TBXA2R (0.76) | TBXA2RTBXAS1HDAC8PSEN1PSEN2 | |
| SCHEMBL15053303 | 0.87 | TBXA2R (0.56) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL15078822 | 0.85 | TBXA2R (0.76) | TBXA2RTBXAS1HDAC8PSEN1PSEN2 | |
| SCHEMBL529887 | 0.85 | TBXA2R (0.76) | TBXA2RTBXAS1HDAC8PSEN1PSEN2 | |
| SCHEMBL529893 | 0.85 | TBXA2R (0.73) | TBXA2RTBXAS1HDAC8PSEN1PSEN2 | |
| SCHEMBL527812 | 0.84 | TBXA2R (1.00) | TBXA2RTBXAS1 | |
| SCHEMBL530268 | 0.84 | TBXA2R (0.72) | TBXA2RTBXAS1HDAC8PSEN1PSEN2 | |
| SCHEMBL15053757 | 0.83 | TBXA2R (0.72) | TBXA2RTBXAS1HDAC8PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927586-B2 | Thromboxane A2 (TP) receptor antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927586-B2 | Thromboxane A2 (TP) receptor antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130190370-A1 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012015944-A2 | NOVEL TETRAHYDRONAPHALENE ANTAGONISTS TO THE THROMBOXANE A2 (TP) RECEPTOR | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190370-A1 | Novel Tetrahydronaphalene Antagonists to the Thromboxane A2 (TP) Receptor | TBXA2R, PTGIR, PTGFR | TBXA2R 1/4885TBXAS1 6/4885HDAC8 4093/4885 |
| US-20130165488-A1 | Novel Thromboxane A2 (TP) Receptor Antagonists | TBXA2R, TBXAS1, PTGIR | TBXA2R 1/4885TBXAS1 2/4885HDAC8 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.